Concurrent Comparison of the Prognostic Values of Tumor Budding, Tumor Stroma Ratio, Tumor Infiltrating Pattern and Lymphocyte-to-Monocyte Ratio in Colorectal Cancer Patients

Yingcheng Zhang, MD1,*, You Liu, BA2,*, Xiaomei Qiu, BA2,*, and Bing Yan, PhD3

Abstract
Objectives: Tumor budding (TB), tumor stroma ratio (TSR), tumor infiltrating pattern (TIP), and preoperative lymphocyte-to-monocyte ratio (LMR) were previously reported to be useful prognostic factors in colorectal cancer (CRC); however, the correlation among these markers and their individual prognostic potency have not been extensively studied. Methods: A cohort of 147 stage I-IV CRC patients was obtained retrospectively, and the patients were divided into subgroups based on low or high TB/TSR/LMR, TIPA (expansile + intermediate) and TIPb (infiltrative) values. The differences in relapse-free survival (RFS) and overall survival (OS) intervals among these subgroups were determined by Kaplan–Meier analysis followed by log-rank tests. The Cox proportional hazard model was applied for the univariate and multivariate analysis of RFS and OS rates. Results: TB, TIP, and LMR, but not TSR, are useful markers for predicting patient survival. Patients with a poor histological grade and large tumor diameter were more likely to present with high TB, TIPb, and low LMR values; in addition, those with advanced T , N, and TNM stages and elevated preoperative CA199 levels had high TB and TIPb levels. TB, TIP, and LMR were significant prognostic factors for the RFS (TB: HR [hazard ratio] = 2.28, 95% CI = 1.30-4.00, P < .01; TIP: HR = 2.60, 95% CI = 1.46-4.60, P < .01; LMR: HR = 0.79, 95% CI = 0.65-0.96, P = .02) and OS (TB: HR = 2.43, 95% CI = 1.32-4.48, P < .01; TIP: HR = 2.49, 95% CI = 1.34-4.63, P < .01; LMR: HR = 0.79, 95% CI = 0.64-0.98, P = .03) intervals. In addition, TB and LMR were independent prognostic factors for the RFS interval (TB: HR = 1.80, 95% CI = 1.01-3.19, P = .05; LMR: HR = 0.80, 95% CI = 0.67-0.96, P = .01), but only LMR was an independent factor for OS rates (HR = 0.80, 95% CI = 0.65-0.98, P = .03). Conclusion: Although TB, TIP, and LMR are useful prognostic markers for CRC, the LMR is likely to be the only independent prognostic factor for both RFS and OS outcomes in practice.

Keywords
colorectal cancer, tumor budding, tumor stroma ratio, tumor infiltrating pattern, lymphocyte-to-monocyte ratio

Introduction
Colorectal cancer (CRC) is still a deadly disease in many countries, including China, and there is a decreasing trend in the age of patients who die from CRC. To date, the majority of metastatic cases of CRC, except for a small cluster featuring high microsatellite instability (MSI) that respond well to immunotherapy, are poorly controlled and patients have poor survival rates. The search for biomarkers that guide not only patient selection for certain therapeutic regimens but can also be used for prognostic prediction is increasingly important.

1 Department of Traditional Chinese Medicine, Second Affiliated Hospital of Naval Medical University, Shanghai, P.R. China
2 Department of Pathology, Hainan Hospital of Chinese PLA General Hospital, Sanya, P.R. China
3 Department of Oncology, Hainan Hospital of Chinese PLA General Hospital, Sanya, P.R. China

*Contribute equally to this work.

Corresponding Author:
Bing Yan, Department of Oncology, Hainan Hospital of Chinese PLA General Hospital, No. 80 of Jianglin Road, Haitang District of Sanya city, Hainan province, 572000, P.R. China.
Email: y_bing41@163.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Previously, a group of biomarkers collected from hematoxylin and eosin (HE) staining slides, including tumor budding (TB), tumor stroma ratio (TSR, also referred to as tumor stroma proportion), and tumor infiltrating pattern (TIP, also referred to as tumor growth pattern), were reported to be useful prognostic indicators in many malignant diseases, including gastric cancer, breast cancer, lung cancer, and CRC. TB is defined as “a single tumor cell or a cell cluster consisting of 4 tumor cells or less” and has been reported to be closely correlated with disease recurrence and poor patient prognosis in CRC. In addition, TSR has also been found to be a predictor of local tumor growth and invasion, and TIP has been found to be associated with disease recurrence in CRC. It is notable that TB, TSR, and TIP are morphological parameters that were collected from HE slides. It is plausible that these parameters are innately connected, and that their individual prognostic potency is not identical; however, few related studies have been conducted.

It is well recognized that systematic inflammatory markers, including the neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR), are simple and reliable prognostic indicators in many malignant diseases, such as head and neck cancer, gastric cancer, pancreatic cancer, breast cancer, and CRC. In particular, the LMR has been proven to be superior for predicting prognosis than other markers, including the NLR, in CRC. Notably, several studies have suggested that TB, TSR, and TIP are associated with cancer-related inflammation; nonetheless, the underlying correlations among TB, TSR, TIP, and LMR have never been reported.

In this study, we aimed to explore the correlation among these markers and determine their individual prognostic potency in CRC.

**Methods**

**Patient Enrollments**

From January 2011 to October 2016, patients who underwent colectomy either laparotomy or laparoscopic surgery were enrolled at the Hainan Hospital of Chinese PLA General Hospital. Patients who met the following criteria were included: 1. age ≥ 18 years old; 2. no neoadjuvant therapies; and 3. radical excision of the primary tumor. The exclusion criteria were as follows: 1. age < 18 years old; 2. complications requiring glucocorticoids or other immunosuppressors; 3. any neoadjuvant therapies; 4. absence of laboratory tests within a week before surgery or key information loss in postoperative pathological reports; 5. multiple or recurrent malignancies, in situ lesions; and 6. lost to follow-up or follow-up period was less than 36 m. Clinicopathological parameters were collected as previously described. The study was approved by the ethics committee of the Hainan Hospital of the PLA General Hospital (approved ID: 301HLFYLS15), and written informed consent was obtained from the patients or his/her authorized relatives.

**Determination of TB, TSR, and TIP and Definition of Subgroups**

Surgical tissue samples were immediately processed by standard pathological procedures in the Department of Pathology as previously described, and 5-μm HE-stained sections were analyzed by conventional microscopy (DM3000, Leica). In brief, the slides were first observed under a 20× objective lens to determine the most invasive front (areas with mucinosity, necrosis or breakage were excluded). TB was defined as “an isolated...
cancer cell or a cluster composed of fewer than 5 cancer cells and was determined according to the recommendations for reporting TB in CRC in the ITBCC 2016. At least 10 individual fields were identified as the “hotspot,” and the final results were divided into low (<5 buds and 5-9 buds) and high (≥10 buds) subgroups as previously reported. For TSR, after selecting

Figure 2. H&E staining to evaluate TB, TSR, TIP: (A) low TB; (B) high TB (black arrows indicate typical budings); (C) low TSR; (D) high TSR; (A-D with magnification × 200); (E) TIP expansile growth pattern; (F) TIP intermediate growth pattern; (G) TIP infiltrating growth pattern (E-G with magnification × 100). Abbreviations: TB, tumor budding; TSR, tumor stroma ratio; TIP, tumor infiltrating pattern.
target areas in the same manner as for TB, areas were chosen
where both tumor (present at all borders of the image field)
and stromal tissue were visible under a 10× objective and
patients were classified into TSR low (≤50%) or high (>50%)
subgroups.19,35 For TIP, the definitions of expansive (the invasive
margin was pushing or well circumscribed), intermediate (large-
to medium-sized glands presented and the border was not clear)
and infiltrative (cancer cells invaded in a diffuse pattern with
extensive penetration of normal tissue, often with no legible
margin) were determined in selected target areas, determined in
the same manner as performed for TB,7,36 and patients were
divided into TIPa (expansile + intermediate) and TIPb (infi-
ltrative) subgroups as in previous studies.7,36 All the parameters
were read by 2 independent senior pathologists who were
blinded to the clinical information of the cohort.

Calculating for LMR
Routine laboratory tests were performed between 6:00 and 9:00
am by peripheral venous blood collection within 1 week before
surgery. The LMR was calculated as previously reported.37

Definition of Relapse-Free Survival (RFS) and Overall
Survival (OS) Intervals
Follow-up was performed by telephone, WeChat or visit as per the
hospital medical records at intervals of 3 to 6 months for the first 3
years and 6 to 12 months for the subsequent 3 years. The RFS
interval was defined as the time between the date of surgery and
the date of the first recurrence at any location, disease progression
identified by imaging or death from any cause. The OS interval
was defined from the date of surgery until the date of death
from any cause. The latest follow-up date was in June 2020.

Statistical Analysis
All statistical analyses were conducted by using SPSS 20.0 (SPSS
Inc.). A receiver operating characteristic (ROC) curve analysis
was used to determine the optimal discriminator value for LMR.
The areas under the curve (AUCs) were compared by MedCalc
v19.0.7 (MedCalc Software Ltd). The differences in clinicopath-
ological parameters among low or high TB/TSR/LMR and TIPa
or TIPb subgroups were calculated by χ²-test or Fisher’s exact
test or Student’s t where appropriate. The associations among
these markers were determined by Spearman’s correlation analy-
sis, Kaplan–Meier (K-M) survival curves were applied to compare
patients in different subgroups, and significance was determined
by log-rank tests. Univariate and multivariate analyses were con-
ducted by using the Cox proportional hazards model. A two-sided
P < .05 was considered statistically significant.

Results
Demographic Characteristics and the Differences in
Clinicopathological Parameters Among TB, TIP, and LMR
Subgroups
In total, 147 colorectal adenocarcinoma patients staged I to IV
(according to the seventh edition of the AJCC) were enrolled
(Figure 1). There were 57 female and 90 male patients, and the
mean age of the patients was 59.87 years (range: 24-85 years)
with a medium follow-up time of 48.81 m (range:
1.00-91.00 m). In the ROC analysis, both TB and TIP, but not
TSR (Figure 2), were useful for predicting survival (Figure 3A), and the LMR had a sensitivity of 50.00% and specificity of 79.40% at the cutoff point of 3.15 (Figure 3B). However, subsequent comparison of the AUCs for TB, TIP, and LMR displayed no significant differences \((P > .05)\). Patients with a poor histological grade and large tumor diameter were more likely to present with high TB and TIPb and low LMR; in addition, those with advanced T, N, and TNM stages as well as elevated CA199 displayed high TB and TIPb (Table 1).

**Predictive Value of TB, TIP, and LMR for Survival Outcomes**

In the K-M analyses, patients with high TB or TIPb had significantly worse RFS (TB low vs high: 49.92 ± 20.30 m vs 38.19 ± 24.98 m, \(P < .01\); TIP a vs b: 50.83 ± 18.88 m vs 37.61 ± 25.71 m, \(P < .01\)) and OS (TB low vs high: 52.90 ± 18.54 m vs 43.33 ± 22.05 m, \(P < .01\); TIP a vs b: 52.80 ± 16.63 m vs 23.80 ± 9.54 m, \(P < .01\)).

### Table 1. Differences of TB, TIP, and LMR Among Different Clinicopathological Parameters.

|                      | TB            | TIP           | LMR           |
|----------------------|---------------|---------------|---------------|
|                      | No. | Low | High | \(P\) | a  | b  | P  | No. | Low | High | P  |
| Age (y)              | .81  | .98 | .48  | .37  | .48 | .05 | .06 | .49  | .49  |   |
| <60                  | 67   | 39  | 28   |       |     |     |     | 19   | 48   |   |
| ≥60                  | 80   | 45  | 35   |       |     |     |     | 27   | 53   |   |
| Gender               | .38  | .84 | .08  | .38  | .48 | .98 | .83 | .21  | .21  |   |
| Female               | 57   | 30  | 27   |       |     |     |     | 13   | 44   |   |
| Male                 | 90   | 54  | 36   |       |     |     |     | 33   | 57   |   |
| Tumor location       | .43  | .10 | .98  | .43  | .10 | .98 | .98 | .43  | .10  | .98 |
| Right                | 35   | 18  | 17   |       |     |     |     | 11   | 24   |   |
| Left                 | 112  | 66  | 46   |       |     |     |     | 35   | 77   |   |
| Histological grade   | .02  | .01 | .01  | .02  | .01 | .01 | .01 | .02  | .01  | .01 |
| Well + moderate      | 118  | 73  | 45   |       |     |     |     | 31   | 87   |   |
| Poor                 | 29   | 11  | 18   |       |     |     |     | 15   | 14   |   |
| CEA level            | .09  | .05 | .06  | .09  | .05 | .06 | .06 | .09  | .05  | .06 |
| Normal               | 93   | 58  | 35   |       |     |     |     | 24   | 69   |   |
| Elevated             | 54   | 26  | 28   |       |     |     |     | 22   | 32   |   |
| CA19-9 level         | .01  | .01 | .01  | .01  | .01 | .01 | .01 | .01  | .01  | .01 |
| Normal               | 119  | 77  | 42   |       |     |     |     | 33   | 86   |   |
| Elevated             | 28   | 7   | 21   |       |     |     |     | 13   | 15   |   |
| TSR                  | .37  | .48 | .20  | .37  | .48 | .20 | .20 | .37  | .48  | .20 |
| Low                  | 130  | 76  | 54   |       |     |     |     | 43   | 87   |   |
| High                 | 17   | 8   | 9    |       |     |     |     | 3    | 14   |   |
| Invasive depth       | .01  | .01 | .05  | .01  | .01 | .05 | .05 | .01  | .01  | .05 |
| \(T_{1+2}\)          | 34   | 28  | 6    | .04  | .04 | .04 | .04 | .04  | .04  | .04 |
| \(T_{3+4}\)          | 113  | 56  | 57   | 3.95 ± 1.39 | 4.79 ± 2.27 | .01 | 5.12 ± 2.22 | 3.96 ± 1.58 | .01 | .01 |
| Maximum tumor diameter (cm) | 147 | 4.04 ± 1.58 | 4.71 ± 2.16 | .04 | .04 | .04 | .04 | .04  | .04  | .04 |
| Node involvement     | <.01 | <.01 | .49  | <.01 | <.01 | .49 | .49 | <.01 | <.01 | .49 |
| N0                   | 86   | 60  | 26   | .26  | .26 | .26 | .26 | .26  | .26  | .26 |
| N1                   | 61   | 24  | 37   | .04  | .04 | .04 | .04 | .04  | .04  | .04 |
| M stage              | .26  |     | .09  | .26  |     | .09 | .26 | .26  |     | .09 |
| 0                    | 137  | 80  | 57   | .10  | .10 | .10 | .10 | .10  | .10  | .10 |
| I                    | 10   | 4   | 6    | .97  | .97 | .97 | .97 | .97  | .97  | .97 |
| TNM stage            | <.01 | <.01 | .64  | <.01 | <.01 | .64 | .64 | <.01 | <.01 | .64 |
| I + II               | 84   | 58  | 26   | .49  | .49 | .49 | .49 | .49  | .49  | .49 |
| III + IV             | 63   | 26  | 37   | .24  | .24 | .24 | .24 | .24  | .24  | .24 |
| Adjuvant therapies   | <.01 | <.01 | .83  | <.01 | <.01 | .83 | .83 | <.01 | <.01 | .83 |
| Received             | 78   | 34  | 44   | .31  | .31 | .31 | .31 | .31  | .31  | .31 |
| None                 | 69   | 50  | 19   | 23.55 ± 3.68 | 22.86 ± 3.49 | .25 | 23.04 ± 3.98 | 23.32 ± 3.43 | .66 | .66 |
| BMI (kg/m²)          | 147  | 23.50 ± 3.82 | 22.88 ± 3.28 | .31 | .31 | .31 | .31 | .31  | .31  | .31 |

Abbreviations: TB, tumor budding; TSR, tumor stroma ratio; TIP, tumor infiltrating pattern; LMR, lymphocyte-to-monocyte ratio; BMI, body mass index; No., number of the patients.

Spearman correlation analyses of TB, TSR, TIP, and LMR indicated no significant correlations among TB, TSR, and LMR, and only TB and TIP showed statistically significant correlations \((r = .63, P < .01)\). Patients with low TB (82.14%) were more commonly found to have TIPa; whereas those with high TB (80.95%) more commonly had TIPb, as revealed by further analysis.
43.89 ± 23.84 m, \(P < .01\) outcomes than those of patients with low TB or TIPa; in contrast, patients with high LMR had significantly poorer RFS (low vs high: 33.11 ± 24.45 m vs 50.26 ± 20.40 m, \(P < .01\)) and OS (low vs 39.17 ± 21.65 m vs 19.11 ± 24.45 m, \(P < .01\)) outcomes (Figure 4).

**Univariate and Multivariate Analyses of the Prognostic Factors for RFS and OS Outcomes**

Univariate tests revealed that TB, TIP, and LMR were significant prognostic factors for RFS (Table 2) and OS outcomes (Table 3); multivariate tests revealed that TB and LMR were independent prognostic factors for RFS outcomes (Table 2), but only LMR was an independent factor for the OS outcome (Table 3).

**Discussion**

In the present study, we found that TB, TIP, and LMR, but not TSR, were useful markers for predicting the survival outcomes of CRC patients. Patients with a poor histological grade and large tumor diameter are likely to present with high TB and TIPb and low LMR. In addition, although both TB and LMR were independent prognostic factors for RFS outcomes, the LMR was the only independent factor for OS outcomes among these markers.

Previously, TB, TSR, and TIP were reported to be important prognostic factors in CRC. Oh et al.\(^{18}\) conducted a study including 4196 staged I to III patients and found that high TB was associated with several adverse clinicopathological parameters, such as advanced stages and poor histological grade, as well as inferior disease-free survival (DFS) and OS outcomes. Similarly, Nagata et al.\(^{12}\) conducted a study of 371 stage IV patients and found that those with a high TB had poor OS outcomes. In addition, TIP has also been reported to be a robust indicator of local or distant recurrence\(^{14,20}\) and of OS outcomes (confined to stage I-III patients) in CRC patients.\(^{36}\) Our results regarding TB and TIP were in line with those of these reports.\(^{12,18,36}\) In addition, the TSR has been found to be an important prognostic marker in CRC, but with conflicting results; for example, Mesker et al.’s\(^{35}\) study revealed that DFS and OS outcomes in patients with a high TSR were remarkably superior, but other reports yielded opposite conclusions.\(^{13,19,38}\) Nonetheless, the TSR failed to predict survival outcomes in our study, even though we excluded stage IV patients according to the recommendations in previous reports.\(^{13,19,35,38}\) We speculate that these findings may be attributable to the relatively low proportion of high TSR levels in our study cohort (11.56%) compared to that reported by others (70.8%,\(^{13}\) 73.00%,\(^{35}\) and 70.51%\(^{39}\)).
Notably, TB, TSR, and TIP are potentially correlated with each other and related to the stroma. For example, a several studies have indicated that TB is associated with TIP, and both TB and TIP have been suggested to be related to TSR. In addition, TB is a marker of cancer cells that undergo epithelial-to-mesenchymal transition; these cells are supported by key signaling molecules such as twist-related protein 1 (TWIST1) and TWIST2 in the surrounding stroma. However, the prognostic potency of these markers may not be identical. Eriksen et al conducted a study that included 573 stage II patients and compared the prognostic role of TB and TSR and found that TB had no prognostic value. In our study, we also found a significant correlation between TB and TIP, both of which are important patient prognostic factors, particularly TB; however, due to the heterogeneity of TSR in our cohort, no correlation was found among TB, TIP, and TSR, and larger study sample sizes are needed in the future.

The preoperative LMR has long been regarded as an important prognostic indicator in CRC. Previously, Stotz et al conducted a study of 372 stage II to III patients and reported that an

### Table 2. Univariate and Multivariate Analyses of Different Parameters for RFS.

| Parameter                      | Univariate |      |      | Multivariate |      |      |
|-------------------------------|------------|------|------|--------------|------|------|
|                               | **P**      | **HR** | **95%CI** | **P** | **HR** | **95%CI** |
| Age (y)                       |            |      |      |              |      |      |
| <60                           | .15        | 1.53 | 0.86-2.73 |      |      |      |
| ≥60                           | .15        | 1.53 | 0.86-2.73 |      |      |      |
| Gender                        |            |      |      |              |      |      |
| Female                        |           |      |      |              |      |      |
| Male                          | .64        | 1.15 | 0.65-2.05 |      |      |      |
| Tumor location                |            |      |      |              |      |      |
| Right                         | .30        | 1.47 | 0.72-3.03 |      |      |      |
| Left                          | .30        | 1.47 | 0.72-3.03 |      |      |      |
| Histological grade            |            |      |      |              |      |      |
| Well + moderate               | .04        | 1.93 | 1.04-3.59 |      |      |      |
| Poor                          | .04        | 1.93 | 1.04-3.59 |      |      |      |
| CEA level                     |            |      |      |              |      |      |
| Normal                        | .02        | 1.92 | 1.10-3.35 |      |      |      |
| Elevated                      | .02        | 1.92 | 1.10-3.35 |      |      |      |
| CA19-9 level                  |            |      |      |              |      |      |
| Normal                        | .01        | 2.39 | 1.30-4.39 |      |      |      |
| Elevated                      | .01        | 2.39 | 1.30-4.39 |      |      |      |
| TSR                           |            |      |      |              |      |      |
| Low                           | .95        | 0.97 | 0.42-2.29 |      |      |      |
| High                          | .95        | 0.97 | 0.42-2.29 |      |      |      |
| Invasive depth                |            |      |      |              |      |      |
| T1+2                          | .05        | 5.96 | 1.86-19.18 |      |      |      |
| T3+4                          | .05        | 5.96 | 1.86-19.18 |      |      |      |
| Maximum tumor diameter (cm)   | .05        | 1.13 | 0.99-1.30 |      |      |      |
| Node involvement              |            |      |      |              |      |      |
| N0                            | .05        | 2.47 | 1.41-4.34 |      |      |      |
| N1+2                          | .05        | 2.47 | 1.41-4.34 |      |      |      |
| M stages                      |            |      |      |              |      |      |
| M0                            | .05        | 8.49 | 4.03-17.86 |      |      |      |
| M1                            | .05        | 8.49 | 4.03-17.86 |      |      |      |
| TNM stage                     |            |      |      |              |      |      |
| I + II                        | .05        | 2.76 | 1.56-4.90 |      |      |      |
| II + IV                       | .05        | 2.76 | 1.56-4.90 |      |      |      |
| Adjuvant therapies            |            |      |      |              |      |      |
| Received                      | .32        | 0.75 | 0.43-1.32 |      |      |      |
| None                          | .32        | 0.75 | 0.43-1.32 |      |      |      |
| BMI (kg/m²)                   | .01        | 0.90 | 0.82-0.98 | .03  | 0.90 | 0.83-0.99 |
| TB                            | .01        | 2.28 | 1.30-4.00 | .05  | 1.80 | 1.01-3.19 |
| TIP                           | .01        | 2.28 | 1.30-4.00 | .05  | 1.80 | 1.01-3.19 |
| LMR                           | .02        | 0.79 | 0.65-0.96 | .01  | 0.80 | 0.67-0.96 |

Abbreviations: TB, tumor budding; TSR, tumor stroma ratio; TIP, tumor infiltrating pattern; LMR, lymphocyte-to-monocyte ratio; RFS, relapse-free survival; BMI, body mass index; HR, hazard ratio.
elevated preoperative LMR was significantly associated with increased OS times, but this was limited to stage III patients. Ozawa et al.44 conducted a study that included 117 stage IV patients and found that LMR was not correlated with DFS outcomes but was linked to cancer-specific survival outcomes in patients who underwent curative resection. Subsequently, Chan et al.29 reported in a study of 1623 stage I to IV patients and found that the LMR was superior for predicting OS outcomes in comparison to the results obtained with other established biomarkers. Recently, Tan et al.26 performed a meta-analysis including 11,783 patients and found that a high LMR was a significant predictor of better DFS and OS outcomes and was also associated with tumor invasion depth and tumor size. In our study, the preoperative LMR was also significantly correlated with histological grade and tumor diameter and boundary linked to invasion depth; in addition, the LMR was an independent prognostic factor for DFS and OS outcomes, which was in line with previous reports.25,26,29

Table 3. Univariate and multivariate analyses of different parameters for OS.

| Parameter                                | Univariate | | | Multivariate | | |
|------------------------------------------|------------|---|---|-------------|---|---|
|                                          | P | HR | 95%CI | P | HR | 95%CI |
|------------------------------------------|------------|---|---|-------------|---|---|
| Age (y)                                  | <.01 | 2.16 | 1.13-4.15 | <.01 | 2.44 | 1.29-4.64 |
| Gender                                   | .43 | 1.30 | 0.69-2.46 | .77 | 0.87 | 0.34-2.21 |
| Tumor location                           | .39 | 1.40 | 0.65-3.01 | .77 | 0.87 | 0.34-2.21 |
| Histological grade                       | .03 | 2.03 | 1.06-3.90 | .03 | 2.03 | 1.06-3.90 |
| CEA level                                | <.01 | 2.34 | 1.28-4.26 | <.01 | 2.44 | 1.29-4.64 |
| CA19-9 level                             | .03 | 1.18 | 1.02-1.36 | <.01 | 2.44 | 1.29-4.64 |
| Invasive depth                           | .07 | 0.92 | 0.51-1.69 | .07 | 0.92 | 0.84-1.01 |
| Maximum tumor diameter (cm)              | .03 | 1.18 | 1.02-1.36 | .03 | 1.18 | 1.02-1.36 |
| Node involvement                         | .01 | 2.12 | 1.16-3.88 | .01 | 2.12 | 1.16-3.88 |
| M stages                                 | .01 | 11.03 | 5.21-23.35 | .01 | 11.03 | 5.21-23.35 |
| TNM stage                                | .01 | 2.81 | 1.51-5.23 | .01 | 2.81 | 1.51-5.23 |
| Adjuvant therapies                       | .80 | 0.92 | 0.51-1.69 | .80 | 0.92 | 0.51-1.69 |
| BMI (kg/m²)                              | <.01 | 2.43 | 1.32-4.48 | <.01 | 2.43 | 1.32-4.48 |
| LMR                                      | .03 | 0.79 | 0.64-0.98 | .03 | 0.79 | 0.64-0.98 |

Abbreviations: TB, tumor budding; TSR, tumor stroma ratio; TIP, tumor infiltrating pattern; LMR, lymphocyte-to-monocyte ratio; RFS, relapse-free survival; BMI, body mass index; HR, hazard ratio; OS, overall survival.
Interestingly, the LMR is believed to be an indicator of the inflammatory process not only at the tumor level but also systemically and can be manipulated by several cytokines, growth factors, and other mediators released by tumor cells and tumor-associated stroma. From this point of view, TB, TSR, and TIP could potentially be associated with LMR; a typical example is TB featuring increased expression of CXCL12, which plays an important role in regulating lymphocytes and monocytes. Surprisingly, no significant correlation was found between TB and peritumoral or intratumoral inflammatory infiltration; additionally, the TSR was not found to be associated with the systemic inflammatory response in a previous report. In our study, we also failed to find a correlation between LMR and TB, TSR, and TIP, and additional studies are still needed in the future.

The present study had some limitations. First, the study was retrospectively performed at a single center, and the limited sample size may have impaired the statistical power and biased the findings; in particular, the relatively small proportion of high TSR in the cohort may have influenced the results. Second, as some patients, in particular those staged III and IV, subsequently received chemotherapy and other therapies after surgery, the final survival outcome of the patients could have been affected by these treatments. Third, the proportion of patients with distant lesions in the cohort was relatively low, and the study of more patients with these characteristics could balance the demographic characteristics. Fourth, some important molecular information, such as MSI and K-Ras status, was lacking. In previous studies, correlations among MSI and TB, TSR, and TIP have been reported. Ultimately, additional studies with larger sample sizes in the future could attenuate these biases and validate the results of this study.

**Conclusion**

In conclusion, our results indicate that TB, TIP, and LMR are useful prognostic markers for CRC; however, LMR is likely to be the only independent prognostic factor for both RFS and OS outcomes.

**Acknowledgments**

The study was conducted with grants from the Chinese Natural Science Foundation (81503391) and Sanya Medical and Health Science Innovation Project (2018YW06 and 2016YW08).

**Ethics Statement**

The study was approved by the ethics committee of Hainan Hospital of PLA General Hospital (approved ID: 301HLFYL51S), and written informed consent was obtained from the patients or his/her authorized relatives.

**Declaration of Conflicting Interests**

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The authors received no financial support for the research, authorship and/or publication of this article.

**ORCID iD**

Bing Yan https://orcid.org/0000-0001-5430-4761

**References**

1. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. *CA Cancer J Clin*. 2020;70(3):145-164.
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. *CA Cancer J Clin*. 2016;66(2):115-132.
3. Vaik FE, Nieuwenburg SA, Bardou M, et al. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. *Gut*. 2019;68(10):1820-1826.
4. Le DT, Uram NJ, Wang H, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. *N Engl J Med*. 2015;372(26):2509-2520.
5. Gulluoglu M, Yegen G, Ozluk Y, et al. Tumor budding is independently predictive for lymph node involvement in early gastric cancer. *Int J Surg Pathol*. 2015;23(5):349-358.
6. Kemi N, Eskuri M, Herva A, et al. Tumour-stroma ratio and prognosis in gastric adenocarcinoma. *Br J Cancer*. 2018;119(4):435-439.
7. Zhao B, Zhang J, Mei D, et al. Prognostic significance of tumour infiltration growth pattern in patients with advanced gastric cancer. *J Clin Pathol*. 2019;72(2):165-171.
8. Kramer CJH, Vangangelt KMH, van Pelt GW, Dekker TJ, Tollenaar RAEM, Mesker WE. The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review. *Breast Cancer Res Treat*. 2019;173(1):55-64.
9. Dekker TJ, van de Velde CJ, van Pelt GW, et al. Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). *Breast Cancer Res Treat*. 2013;139(2):371-379.
10. Xi KX, Wen YS, Zhu CM, et al. Tumor-stroma ratio (TSR) in non-small cell lung cancer (NSCLC) patients after lung resection is a prognostic factor for survival. *J Thorac Dis*. 2017;9(10):4017-4026.
11. Marx AH, Mickler C, Sauter G, et al. High-grade intratumoral tumor budding is a predictor for lymphovascular invasion and adverse outcome in stage II colorectal cancer. *Int J Colorectal Dis*. 2020;35(2):259-268.
12. Nagata K, Shinto E, Yamadera M, et al. Prognostic and predictive values of tumour budding in stage IV colorectal cancer. *BJS Open*. 2020;4(4):693-703.
13. Park JH, Richards CH, McMillan DC, Horgan PG, Roxburgh CSD. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. *Ann Oncol*. 2014;25(3):644-651.
14. Pinheiro RS, Herman P, Lupinacci RM, et al. Tumor growth pattern as predictor of colorectal liver metastasis recurrence. *Am J Surg*. 2014;207(4):493-498.
15. Lugli A, Kirsch R, Ajjoka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the international
tumor budding consensus conference (ITBCC) 2016. Mod Pathol. 2017;30(9):1299-1311.

16. Ueno H, Ishiguro M, Nakatani E, et al. Prospective multicenter study on the prognostic and predictive impact of tumor budding in stage II colon cancer: results from the SACURA trial. J Clin Oncol. 2019;37(22):1886-1894.

17. Landau MA, Zhu B, Akwule FN, Pai RK. Histopathological predictors of recurrence in stage III colon cancer: reappraisal of tumor deposits and tumor budding using AJCC8 criteria. Int J Surg Pathol. 2019;27(2):147-158.

18. Oh BY, Park YA, Huh JW, et al. Prognostic impact of tumor-budding grade in stages I-3 colon cancer: a retrospective cohort study. Ann Surg Oncol. 2018;25(1):204-211.

19. Huijbers A, Tollenaar RA, v Pelt GW, et al. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol. 2013;24(1):179-185.

20. Tokodai K, Narimatsu H, Nishida A, et al. Risk factors for recurrence in stage II/III colorectal cancer patients treated with curative surgery: the impact of postoperative tumor markers and an infiltrative growth pattern. J Surg Oncol. 2016;114(3):368-374.

21. Tham T, Olson C, Khaymovich J, Herman SW, Costantino PD. The lymphocyte-to-monocyte ratio as a prognostic indicator in head and neck cancer: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol. 2018;275(7):1663-1670.

22. Ma JY, Liu Q. Clinico-pathological and prognostic significance of lymphocyte to monocyte ratio in patients with gastric cancer: a meta-analysis. Int J Surg. 2018;50:67-71.

23. Hu RJ, Ma JY, Hu G. Lymphocyte-to-monocyte ratio in pancreatic cancer: prognostic significance and meta-analysis. Clin Chim Acta. 2018;481:142-146.

24. Hu RJ, Liu Q, Ma JY, Zhou J, Liu G. Preoperative lymphocyte-to-monocyte ratio predicts breast cancer outcome: a meta-analysis. Clin Chim Acta. 2018;484:1-6.

25. Stotz M, Pichler M, Absenger G, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014;110(2):435-440.

26. Tan D, Fu Y, Tong W, Li F. Prognostic significance of lymphocyte to monocyte ratio in colorectal cancer: a meta-analysis. Int J Surg. 2018;55:128-138.

27. Wu Q, Hu T, Zheng E, Deng X, Wang Z. Prognostic role of the lymphocyte-to-monocyte ratio in colorectal cancer: an up-to-date meta-analysis. Medicine (Baltimore). 2017;96(22):e7051.

28. Shibutani M, Maeda K, Nagahara H, Iseki Y, Ikeya T, Hinakawa K. Prognostic significance of the preoperative lymphocyte-to-monocyte ratio in patients with colorectal cancer. Oncol Lett. 2017;13(2):1000-1006.

29. Chan JC, Chan DL, Diakos CI, et al. The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer. Ann Surg. 2017;265(3):539-546.

30. Guthrie GJ, Roxburgh CS, Richards CH, Horgan PG, McMillan DC. Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer. Br J Cancer. 2013;109(1):131-137.

31. Xu R, You J, Li F, Yan B. Postoperative fasting blood glucose predicts prognosis in stage I-II colorectal cancer patients undergoing resection. Gastroenterol Res Pract. 2020;2020:2482409.

32. Yan B, Mu Y, Cui MQ, Liu L. Clinico-pathological significance and prognostic implication of CD44 and its splice variants (v3 and v6) in colorectal cancer. Transl Cancer Res. 2020;9(2):1215-1224.

33. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002;40(2):127-132.

34. Kemi N, Eskuri M, Ikäläinen J, Karttunen TJ, Kauppila JH. Tumor budding and prognosis in gastric adenocarcinoma. Am J Surg Pathol. 2019;43(2):229-234.

35. Mesker WE, Jungeblut JM, Szuhai K, et al. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol. 2007;29(5):387-398.

36. Morikawa T, Kuchiba A, Qian ZR, et al. Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol. 2012;19(6):1944-1953.

37. Neofytou K, Smyth EC, Giakoustidis A, et al. The preoperative lymphocyte-to-monocyte ratio is prognostic of clinical outcomes for patients with liver-only colorectal metastases in the neoadjuvant setting. Ann Surg Oncol. 2015;22(13):4353-4362.

38. Fu M, Chen D, Luo F, et al. Association of the tumour stroma percentage in the preoperative biopsies with lymph node metastasis in colorectal cancer. Br J Cancer. 2020;122(3):388-396.

39. Eriksen AC, Sørensen FB, Lindebjerg J, et al. The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study. Int J Colorectal Dis. 2018;33(8):1115-1124.

40. Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol. 2009;33(1):134-141.

41. De Smied L, Palmins S, Andel D, et al. Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching. Br J Cancer. 2017;116(1):58-65.

42. Grigore AD, Jolly MK, Jia D, Farach-Carson MC, Levine H. Tumor budding: the name is EMT. Partial EMT. J Clin Med. 2016;5(5):51.

43. Zlobec I, Lugli A. Tumour budding in colorectal cancer: molecular rationale for clinical translation. Nat Rev Cancer. 2018;18(4):203-204.

44. Ozawa T, Ishihara S, Kawai K, et al. Impact of a lymphocyte to monocyte ratio in stage IV colorectal cancer. J Surg Res. 2015;199(2):386-392.

45. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as onco-target. Oncotarget. 2010;1(7):651-661.

46. Janssens R, Boff D, Ruytinx P, et al. Peroxynitrite exposure of CXCL12 impairs monocyte, lymphocyte and endothelial cell chemotaxis, lymphocyte extravasation in vivo and anti-HIV-1 activity. Front Immunol. 2018;9:1933.
47. Blades MC, Ingegnoli F, Wheller SK, et al. Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID mice. *Arthritis Rheum.* 2002;46(3):824-836.

48. Fonseca GM, de Mello ES, Faraj SF, et al. Prognostic significance of poorly differentiated clusters and tumor budding in colorectal liver metastases. *J Surg Oncol.* 2018;117(7):1364-1375.

49. Lugli A, Vlajnic T, Giger O, et al. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients. *Hum Pathol.* 2011;42(12):1833-1840.